Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers

T. E. Keane, G. Rosner, J. T. Donaldson, D. L. Norwood, S. H. Poulton, P. J. Walther

Research output: Contribution to journalArticlepeer-review

Abstract

The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.

Original languageEnglish (US)
Pages (from-to)1004-1009
Number of pages6
JournalJournal of Urology
Volume144
Issue number4
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Dipyramidole-cisplatin potentiation: Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers'. Together they form a unique fingerprint.

Cite this